Phase I Pharmacokinetic Study of the VEGFR Tyrosine Kinase Inhibitor Vatalanib (PTK787) plus Imatinib and Hydroxyurea for Malignant Glioma

BACKGROUND: We determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of the oral vascular endothelial growth factor receptor (VEGFR) inhibitor, vatalanib, when administered with imatinib and hydroxyurea on a continuous daily schedule among recurrent malignant glioma patients...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Reardon, David A., Egorin, Merrill J., Desjardins, Annick, Vredenburgh, James J., Beumer, Jan H., Lagattuta, Theodore F., Gururangan, Sridharan, Herndon, James E., Salvado, August J., Friedman, Henry S.
Formato: Artigo
Idioma:Inglês
Publicado: 2009
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2691174/
https://ncbi.nlm.nih.gov/pubmed/19248046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.24213
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares